Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Addex Therapeutics Ltd. Sponsored ADR (ADXN : NSDQ)

• Company Description    Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $8.50 Daily Weekly Monthly 20 Day Moving Average: 22,562 shares Shares Outstanding: 1.06 (millions) Market Capitalization: $9.01 (millions) Beta: 1.37 52 Week High: $12.05 52 Week Low: $6.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.96% -12.32% 12 Week 7.05% 2.61% Year To Date 21.43% 6.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL CHEMIN DES MINES 9 - GENEVA,V8 CH-1202 CHE ph: 011-41-22-884-1555 fax: 41-22-884-1556 investor.relations@addextherapeutics.com http://www.addextherapeutics.com/en

• General Corporate Information    Officers Tim Dyer - Chief Executive Officer Vincent Lawton - Chairman Raymond Hill - Director Isaac Manke - Director Jake Nunn - Director Peer Information Addex Therapeutics Ltd. Sponsored ADR (GSAC) Addex Therapeutics Ltd. Sponsored ADR (CASI) Addex Therapeutics Ltd. Sponsored ADR (ALCD.) Addex Therapeutics Ltd. Sponsored ADR (OMNN) Addex Therapeutics Ltd. Sponsored ADR (CGPI.) Addex Therapeutics Ltd. Sponsored ADR (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00654J206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/01/25 Share - Related Items Shares Outstanding: 1.06 Most Recent Split Date: 10.00 (0.05:1) Beta: 1.37 Market Capitalization: $9.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/01/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.03 Price/Cash Flow: - Price / Sales: 32.59 EPS Growth vs. Year Ago Period: -64.41% vs. Previous Quarter: -118.80% Sales Growth vs. Year Ago Period: -70.63% vs. Previous Quarter: 3,291.29% ROE 09/30/25 - - 06/30/25 - -68.40 03/31/25 - -54.27 ROA 09/30/25 - - 06/30/25 - -60.68 03/31/25 - -49.15 Current Ratio 09/30/25 - - 06/30/25 - 2.31 03/31/25 - 3.02 Quick Ratio 09/30/25 - - 06/30/25 - 2.31 03/31/25 - 3.02 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -2,307.03 Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - 3,584.49 Pre-Tax Margin 09/30/25 - - 06/30/25 - -4,812.93 03/31/25 - -2,307.03 Book Value 09/30/25 - - 06/30/25 - 8.25 03/31/25 - 8.71 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©